Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elvitegravir CSF PK in HIV
NCT02251236Completed
- Sponsor
- University of California, San Diego
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by University of California, San Diego. Primary endpoints: Concentration of Elvitegravir in Cerebrospinal Fluid at Week 24 and Concentration of Tenofovir in Cerebrospinal Fluid at Week 24. Started Jan 2016; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02251236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251236.